SIMCERE PHARMA (02096): Xianbixin Sublingual Tablets Included in the New National Reimbursement Drug List

SIMCERE PHARMA (02096) announced that on November 14, 2026, Xianbixin Sublingual Tablets (Edaravone and Dexborneol Sublingual Tablets) were officially included in the "National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2026)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, effective from January 1, 2027. In addition, Xianbixin Injection successfully completed its third medical insurance renewal. Both Xianbixin Injection and Sublingual Tablets are included in the National Reimbursement Drug List, which is expected to achieve medical insurance coverage for the full 14-day course of treatment for acute ischemic stroke (AIS), promote innovative brain cytoprotective treatment regimens benefiting more stroke patients, and reduce patients' medication burden. Xianbixin Sublingual Tablets are a brain cytoprotective agent composed of edaravone and dexborneol, with antioxidant, anti-inflammatory and synergistic effects, capable of significantly reducing brain cell damage caused by AIS. The unique sublingual tablet formulation disintegrates rapidly upon contact with saliva and is quickly absorbed into the bloodstream through the sublingual venous plexus to exert its therapeutic effect, increasing the flexibility of stroke treatment approaches. Xianbixin Sublingual Tablets can form a sequential therapy with Xianbixin Injection, helping patients obtain a complete course of treatment both in hospital and after discharge. Xianbixin Sublingual Tablets were approved for marketing in China in December 2024 for improving neurological symptoms, activities of daily living and functional impairment caused by AIS. In August 2024, Xianbixin Sublingual Tablets received "Breakthrough Therapy" designation from the FDA, becoming the first innovative drug in the global stroke treatment field to receive this designation, and also the first innovative drug in China's neuroscience field to receive this designation.